Physician profile
Patrick C Lee
NPI 1316986318
$10,712.80
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,702 · 2020: $998 · 2022: $12.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $8,580.00 | 2019 | |
| Sanofi Pasteur INC. | $867.71 | 2019 | |
| Boston Scientific Corporation | $798.31 | 2020 | |
| Portola Pharmaceuticals, LLC | $131.05 | 2020 | |
| Organogenesis INC. | $111.25 | 2019 | |
| Stryker Corporation | $68.17 | 2020 | |
| Conmed Corporation | $62.50 | 2019 | |
| Olympus America INC. | $25.79 | 2019 | |
| Convatec INC. | $24.01 | 2019 | |
| 3m Company | $16.88 | 2019 | |
| Osiris Therapeutics INC. | $14.23 | 2019 | |
| Celgene Corporation | $12.90 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.